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Summary Cellular DNA content of primary tumours from 280 patients with operable breast cancer was
determined by flow cytometry using nuclei from paraffin sections stained with DAPI, and 199 of these
patients were followed for 8-13 years after surgery. Tumours from 67 patients have also been analyzed for
their DNA content using single cell suspensions from fresh tumour tissue stained with mithramycin and
ethidium bromide, and the results compared with those obtained from paraffin blocks of the same tumours.
Overall 60% of the tumours contained cells with abnormal DNA content (DNA-aneuploid populations).
Survival and disease free interval were not significantly different in patients with DNA-diploid and DNA-
aneuploid tumours when analysed by Mantel's life table method. There was however, an early advantage for
patients with DNA-diploid tumours: during the first 30 months after surgery DNA-aneuploidy was associated
with higher rate of recurrence and shorter survival. DNA-aneuploidy was strongly related to histological
grade. Thus 11/49 (22%) grade I, 60/102 (59%) grade II, and 96/129 (74%) grade III tumours were DNA-
aneuploid. Although there was no significant difference in survival of patients with DNA-diploid and DNA-
aneuploid tumours overall, there appears to be an unexpected association between DNA-aneuploidy and
better survival in grade II patients (P<0.01); a similar trend was observed for grade I patients. Although the
proportion of DNA-aneuploid tumours was similar in oestrogen receptor positive and negative tumours,
DNA-aneuploidy was associated with lower levels of oestrogen receptors in comparison to DNA-diploid
tumours. Comparison between the modal DNA values of fresh and paraffin embedded samples showed high
rate of comparability (64/67, P<0.0001).
The DNA content of the cells in a tumour is becoming a
frequently measured tumour characteristic. It is a feature
which is variable between tumours of a given site (Atkin &
Richards, 1956), and as it involves evaluation of a degree of
abnormality in the genetically heritable components of the
cell, might be expected to relate to the biological behaviour
of the tumour. However, the significance of this putative
relationship between abnormal DNA content and biological
behaviour with respect to the clinical outcome with different
types of tumour is still not fully established.
Many studies have shown significant correlations in breast
cancer between cellular DNA content and other clinical and
pathological features of the tumour suggestive of poor
clinical outcome for patients with DNA-aneuploid tumours
(see e.g. Olszewski et al., 1981; Fossa et al., 1982; Raber et
al., 1982; Taylor et al., 1983; Auer et al., 1984; Hedley et al.,
1985; Thorud et al., 1986). A few studies have shown a
significant difference in the survival of patients with diploid
and aneuploid tumours (Atkin 1972; Atkin & Kay 1979;
Auer et al., 1980; 1984) and in the disease-free interval (Auer
et al., 1984; Ewers et al., 1984; Hedley et al., 1984; 1985).
However, studies in other centres have not found such
correlations or the correlations did not reach statistical
significance (Raber et al., 1982; Taylor et al., 1983; Coulson
et al., 1984; Stuart-Harris et al., 1985).
Therefore, the significance of the presence of a cell
population with abnormal DNA content in breast cancer has
not been fully resolved. More work is needed to define the
influence of this tumour characteristic on patient survival,
and its relationship to other features and properties of the
tumour of known prognostic significance.
This paper describes our investigations into the
determination of cellular DNA content in primary breast
cancer, including comparison between techniques using fresh
tumour tissue and nuclei derived from paraffin embedded
tumours, and the prognostic significance of aneuploidy
determined by these methods. A subsequent paper will
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explore in more detail the interrelationships between cellular
DNA content and clinico-pathological features of the
tumour, and how these are in turn related to clinical
outcome in different subgroups of patients (Dowle et al.,
1987).
Materials and methods
Patients
Tumour samples were obtained from patients with primary
operable invasive breast cancer. These patients were from a
consecutive series under the care of a single surgical team,
treated by simple mastectomy. Triple lymph node biopsy was
undertaken at mastectomy for histopathological staging:
patients without lymph node involvement were stage A; only
lower axillary involvement stage B; and upper axilla or
internal mammary chain involvement stage C. No further
treatment was given until recurrence, when patients were
given endocrine or chemotherapy.
Analysis offixed tissue
Nuclei from 30,um sections of paraffin embedded tumour
tissue were analysed for nuclear DNA content. 5,um sections
were also obtained and examined histologically to confirm
the presence of malignant cells in the material analysed.
Essentially following the procedure of Hedley et al., 1983,
two sections were dewaxed in xylene, rehydrated in graded
alcohols, and digested in pepsin (Sigma, 0.5% in saline
pH 1.5) in a 37°C water bath with frequent vortexing. Nuclei
isolated after centrifugation were stained with diaminido-
phenyl indol (DAPI, Sigma) (1 Mg-1), and held on ice until
analysed.
Analysis offresh tumours
Fresh tumour samples were obtained from 67 consecutive
patients of the same series and put in sterile minimum
essential medium (MEM) and kept at 4°C until analysed
within 24h of surgery. The tumour sample was chopped into
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2-3 mm3 pieces and treated with 10ml collagenase
(0.5mgml-1) (type I, Boehringer Mannheim) and 2-3 drops
of 0.02% DNAase, to prevent cells clumping. The mixture
was gently mixed with a magnetic stirrer for 20min at 37°C.
Dissociated nucleated cells were washed twice with Hanks'
salt medium and 2 x 105 tumour cells in 0.1 ml were mixed
with 0.1% Triton X100 for 1 min, to render the cell
membrane permeable to the staining fluorochromes, and
then treated with 0.5ml of ethidium bromide (final
concentration 15 ugml-') (Sigma) and mithramycin (final
concentration 37.4ugml-1) (Sigma). After 30min incubation
at 4°C the cells were analysed by flow cytometry.
Flow cytometry
Flow analysis was done using FACS IV (Becton Dickinson
FACS system). DAPI fluorescence was excited using 40mW
UV light from an argon laser and collected via a 488 band
pass filter with a 10nM bandwidth. The mean coefficient of
variation of the GO/GI peak was 6.6% (range 4.9-8.7).
Mithramycin fluorescence was excited using 120mW light at
457nM from an argon laser and fluorescence collected via
520 long pass filters.
DNA index (DI) was determined according to a recently
suggested convention on nomenclature for DNA cytometry
(Hiddemann et al., 1984). Thus DI was defined as the ratio
of the mode of the relative DNA content of the GO/GI cells
of the sample divided by the mode of the relative DNA
measurement of the diploid GO/GI reference cells. Cells with
a normal diploid karyotype have, by definition a DI of 1.0
(Figure la). A DNA histogram was said to contain a DNA-
aneuploid population when at least two separate GO/GI
peaks were demonstrable (Figure lc) and DI greater or
lower than 1.0. Where the putative aneuploid peak was at or
near the G2 position (DI 1.9-2.1), an arbitary cut-off point
was used, so that peaks containing more than 15% of the
cells in the distribution were defined as DNA-aneuploid.
Normal human lymphocytes were stained by the same
procedure with each batch of fresh tumours analysed and
run before the samples to calibrate the instrument for the
position of GO/GI normal DNA-diploid peak. Each tumour
sample is a suspension of normal and malignant cells and
the normal cells in the tumour sample, identified by the
position of their peak on the same channel of the prerun
normal lymphocytes, were used as internal diploid standard
for DI calculation.
For the paraffin embedded samples no internal standard,
apart from the normal cells within the tumour sample, was
used as neither chicken RBC nor human peripheral
lymphocytes give consistent ratios to the diploid peak when
added to the pepsin digests of embedded tissue (Hedley et
al., 1983). Therefore, the first peak in the histogram was
considered as GO/GI normal diploid standard.
For the purposes of comparison of data from fresh and
paraffin sections, the DI for the tumours found to be
hypodiploid in the' analysis of fresh tissue were recalculated
assuming the first peak to be diploid, as is done for the
paraffin sections.
Histological grading
Histological assessment was done by a modification of the
method of Bloom and Richardson, 1957 (Elston et al., 1982).
Tumours are graded on a scale from grade I (well
differentiated), to grade III (poorly differentiated), using a
scoring system which takes into account tubule formation,
nuclear pleomorphism, and mitotic activity.
Oestrogen receptors assay
The assays have been performed by Tenovus institute
(Cardiff) by the dextran coated charcoal method (Nicholson
et al., 1981). Oestrogen receptor was considered positive
when a value of greater than 5fmolmg-1 cytosol was found.
Prognostic grouping ofpatients
Prognostic index was calculated according to Haybittle et al.,
1982. This index takes account of the size, lymph node stage,
and histological grade of tumours to allocate patients into
one of three prognostic groups. The groups are: (1) a good
prognosis group whose survival is similar to that of a non-
cancerous aged matched population, (2) a moderate
prognosis group, and (3) a poor prognosis group whose
survival at 5 years is <20%.
Statistical evaluation ofsurvival and disease
free interval (DFI)
Mantel's life table analysis was used to compare survival and
DFI between different patient groups.
Results
Distribution ofDI values
Overall, 60% (167/280) of the primary breast tumours
examined contained DNA-aneuploid cell populations. The
distribution of DI values is shown in Figure 2. The
aneuploid DNA indices show a relatively narrow
distribution, with the majority of values between 1.6 and 2.0.
Comparisonfixed andfresh samples
Results of analysis of paraffin sections (Figure la, c) with
those obtained by conventional analysis of fresh tumour
specimens from the same patients (Figure lb, d), showed
comparable DNA histograms, and 64/67 showed comparable
DI (Figure 3). Applying Student's t-test to the differences
between the DI values of the two methods showed a to-value
of 1.5144 (not significant). The expected difference between
c
n
co -C
CL
L.)
Figure 1 DNA histograms from two primary breast carcinomas:
paraffin section nuclei (a, c) and fresh tumour tissue (b, d) of
DNA-diploid (a, b) and DNA-aneuploid (c, d) tumours.DNA-ANEUPLOIDY IN PIkIMARY BREAST CANCER 451
1 1.5 2 2.5 3.0
DNA index
Figure 2 Distribution of DNA index (DI) values for 280 primary breast carcinomas.
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Figure 4 Disease free survival of patients with DNA-diploid
(A) and DNA-aneuploid (-) breast carcinomas, analysed by
Mantel's life table method.
Table 1 Correlation of DI to recurrence in
2 years and after 2 years
0
Di, fresh tissue
Figure 3 Comparison of DNA index (DI) for 67 tumours
determined by analysis of fresh tumour tissue and paraffin
section nuclei.
the DI values obtained by the two methods, at 95%
confidence, lies in the range +0.07 and -0.009.
DNA ploidy and recurrence
The results of long term follow up of 199 patients with
primary operable breast cancer showed that at the end of 8
years there was no difference in the rate of recurrence of
DNA-diploid and DNA-aneuploid tumours (Figure 4).
DNA-aneuploid tumours, however, were more likely to recur
in the first 2 years following the removal of the primary
tumour, than DNA-diploid tumours (Table I), although
there was no difference in the overall disease free interval
<2 years > 2years
DNA-diploid 22(33%) 28(52%)
DNA-aneuploid 44(66%) 26(48%)
x2=4.19; P<0.05.
(Figure 4). Also, there was no difference in survival after
recurrence between patients with DNA-diploid and DNA-
aneuploid tumours.
DNA ploidy and survival
Overall survival of the patients was not significantly different
between those with DNA-diploid and DNA-aneuploid
tumours after 8-13 years follow up when tested by Mantel's
life table analysis (Figure 5). There is an early difference in
the survival of the two groups of patients which is
statistically significant at 30 months (X2 3.768, P<0.05),
which agrees with the observations of the others on short
follow up (Hedley et al., 1985). However, by 3 years after
surgery, there is little difference in survival. Tetraploid
tumours have been shown to have a similar disease course to
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Figure 5 Survival of patients with DNA-diploid (-) and DNA-
aneuploid (0) breast carcinoma, analysed by Mantel's life table
method.
DNA-diploid tumours in several studies (Atkin, 1972; Auer
et al., 1980; 1984). When tetraploid tumours were excluded
from our analysis, there was still no significant difference in
the survival of patients with DNA-aneuploid and DNA-
diploid tumours.
Relationship between DNA ploidy and histological grade
DNA ploidy was strongly related to the histological grade of
differentiation of the tumours (P<0.0001; Table II). Thus
well differentiated tumours were predominantly DNA-
diploid (78%) whilst the poorly differentiated tumours were
mostly DNA-aneuploid (74%). In view of the strong
prognostic significance of histological grade (Elston et al.,
1982), and the weakness of the relationship between ploidy
and survival shown above, it is surprising that such a strong
correlation is observed between ploidy and grade.
Furthermore, detailed analysis shows that DNA-aneuploidy
tends to be associated with better survival in patients with
grade I and II tumours (Figure 6a, b). This relationship was
significant with grade II (P<0.01). No difference in overall
survival between patients with DNA-aneuploid and DNA-
diploid tumours was observed in grade III patients (Figure 6c).
Table II Correlation between ploidy and histological grade
Grade I Grade II Grade III
DNA-diploid 38(78%)* 42(41%) 33(26%)
DNA-aneuploid 11(22%) 60(59%) 96(74%)
x =26.1036; P<0.000I
*percentage of cases within each grade.
Relationship between DNA ploidy and ER level
Oestrogen receptor status had been assessed in 252 of the
cases studied by DNA analysis. The level of ER varied
between 0-396fmolmg-1 cytosol. One hundred and twenty-
one of the tumours (48%) had an ER level >5ffmolrmg-1
cytosol, conventionally defined as the ER+ group. The
distribution of DNA-diploid and DNA-aneuploid tumours
was not significantly different in the ER+ and ER- groups
defined in this way. However, DNA-diploid tumours were
associated with higher levels of ER, whereas DNA-aneuploid
tumours were associated with lower levels (Table III). This
correlation was statistically significant (X2 6.475, P<0.05).
Relationship between DNA ploidy and lymph node stage
There was no statistically significant relationship between
DNA ploidy and tumour metastasis to regional lymph nodes
defined by histopathological examination of nodes sampled
at the time of mastectomy (Table IV).
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Figure 6 Survival of patients with DNA-diploid (A) and DNA-
aneuploid (0) tumours according to histological grade: grade I
(a.), grade II (b.) and grade III (c.).
Table III Correlation of DI with ER level
ER value,fmolmg- cytosolprotein
<6 6-10 11-50 >50
DNA-diploid 42(42%)* 2(2%) 25(25%) 31(31%)
DNA-aneuploid 79(52%) 9(6%) 24(16%) 40(26%)
X2=6.475; P<0.5.
*percentage of cases within each ploidy type.
Table IV Correlation of DI to stage
A B C
DNA-diploid 66(44%) 29(35%) 18(38%)
DNA-aneuploid 84(56%) 54(65%) 29(62%)
x2=1.921, ns.
Relationship between DNA ploidy andprognostic grouping
Grouping the patients according to the prognostically
significant pathological features (Nottingham prognostic
index), showed significant difference in the distribution of
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Table V Correlation of DI to prognostic groups
Good Moderate Poor
DNA-diploid 27 40 13
DNA-aneuploid 18 69 32
%2=9.499; P<O.005.
DNA-diploid and DNA-aneuploid tumours within these
groups (P<O.001) (Table V). DNA-diploid tumours were
more likely to be associated with good or moderate
prognosis (49 and 52/112, respectively), while DNA-
aneuploid tumours were more likely to be associated with
moderate or poor prognosis (91 & 37/166, respectively).
Discussion
In this study we found that DNA analysis of paraffin
embedded tissue gave DNA index results that were in
general comparable with those obtained by analysis of a
fresh tissue sample, confirming the experience of Hedley et
al., 1983. There were two cases of disagreement where an
aneuploid population was found from analysis of a paraffin
section but not after dissociation of fresh tissue. It was
suspected that selective loss of malignant cells during tissue
dissociation might be a source of this type of disagreement
between methods, although this seems to occur relatively
infrequently. There was also an example of a tumour in
which an aneuploid population found on analysis of fresh
tissue was not found in the paraffin section material. This
was presumably due to heterogeneity within the tumour, and
further studies may be required to define the frequency with
which this variation occurs.
The generally good agreement between methods enabled
us to use archival material to look retrospectively at the
relationship between abnormal DNA content and clinical
course and survival of a consecutive series of patients with
primary operable tumour who have undergone simple
mastectomy and no further therapy until recurrence.
These data show that there is a complex relationship
between tumour DNA ploidy and patient survival. Thus,
DNA-aneuploidy correlates significantly with other features
known to be associated with poor prognosis in breast cancer,
including poor histological grade and lower levels of
oestrogen receptors, as has been found by others (for e.g.,
Fossa et al., 1982; Olszewski et al., 1981; Raber et al., 1982;
Taylor et al., 1983; Hedley et al., 1984). We also show here a
significant correlation to the Nottingham prognostic index,
which takes into account tumour size, regional lymph node
involvement, and histological grade. Although there was no
significant relationship between DNA aneuploidy and stage,
it is surprising that patients with DNA-aneuploid tumours
do not suffer a significantly worse survival overall.
It should be pointed out that there is poorer survival of
patients with DNA-aneuploid tumours in short term follow
up, as judged by Chi square analysis of survival during the
first 30 months after surgery. However, longer follow up
fails to show any difference in the survival of patients with
DNA-diploid and DNA-aneuploid tumours.
Disease free survival is also not significantly different
between patients with DNA-diploid and DNA-aneuploid
tumours, according to Mantel's life table analysis. DNA-
aneuploid tumours tended to recur more quickly, in the first
two years following removal of the primary tumour, in
contrast to DNA-diploid tumours in which the recurrences
were more evenly distributed through the follow-up period.
This difference in the recurrence rate in the early years of
follow up is in agreement with the studies of the others
(Ewers et al., 1984; Hedley et al., 1984; 1985; Thorud et al.,
1986), and is consistent with the findings of others who take
two different time points of follow up to reflect the disease
free survival significance of DNA ploidy (Auer et al., 1984).
Survival after recurrence was not different whether the
tumour was DNA-diploid or DNA-aneuploid, in agreement
with the observation of Stuart-Harris et al., (1985). Also,
there was no apparent relationship between response to
treatment and DNA-aneuploidy.
There appears to be some inconsistency between the
results of studies using static cytometry (e.g. Auer et al.,
1984) and flow methods. This may reflect a difference in
sensitivity, as flow methods may not detect small
populations of aneuploid cells which might be selected for
measurement in static cytometry. However, it is clear that
there are many patients whose tumours contain frank, easily
detected DNA-aneuploid populations, but whose prognosis
is not poor in comparison with similar patients with DNA-
diploid tumours.
Another complex aspect of the relationship between DNA-
aneuploidy and survival is the interaction with histological
grade. Thus there appears to be longer survival of patients
with DNA-aneuploid tumours that are moderately
differentiated (grade II), in comparison with DNA-diploid
tumours of the same histological grades. A similar trend is
observed for grade I patients, although there are few DNA-
aneuploid tumours in this group, and the difference is not
significant by life table analysis. The failure of a subgroup of
patients with DNA-aneuploid breast tumours to do badly in
comparison to their DNA-diploid counterparts is not
without precedent. For example, in a small group of patients
undergoing treatment for advanced disease, Stuart-Harris et
al., (1985) found a trend for patients with DNA-aneuploid
tumours to survive better.
Further explanation is required for the paradox that
although DNA-aneuploidy is strongly related to histological
grade, and grade is strongly related to survival, DNA-
aneuploidy is not predictive of poor survival. One possibility
is that DNA-aneuploidy correlates with an element of grade
that does not strongly relate to survival. To investigate this
point, comparisons have been made between DNA-
aneuploidy and objective measurements of nuclear features
of some of the tumours in this study; the detail of these
measurements will be reported separately (Ellis et al., in
preparation). DNA-diploid tumours were found to be
associated with smaller size nuclei with limited variations in
nuclear area and perimeter and almost all DNA-diploid
tumours were associated with the lowest rate of mitosis,
whereas DNA-aneuploid tumours were associated with
larger nuclei with a wide range of variation in nuclear area
and perimeter, and contained a wide range of mitotic
activity. This suggests that low proliferative activity is found
in DNA-diploid tumours, in contrast to DNA-aneuploid
tumours where an extended range of proliferative activity
was observed. When the patients were grouped into different
survival groups according to these nuclear morphometric
measurements and mitotic rate, the long survival groups
were predominantly DNA-diploid. DNA-aneuploid tumours
were distributed over a wide range of survival, which seems
to obscure the survival advantage of DNA-diploid tumours.
These studies show that DI is a marker which relates to
prognostically significant features in breast cancer, and
DNA-diploidy may in particular be associated with low
proliferative activity. However, DI is not useful as a single
marker for prediction of survival. More detailed analysis will
be required to assess the possibility of using DI as a factor,
with the other prognostically significant parameters,
contributing to prognosis in primary breast cancer.
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